Genetically engineered tumor cell vaccines
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 17, 2002
app pub date -
Jan 26, 2001
filing date -
Jan 27, 2000
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention provides a composition for stimulating an immune response in a patient having an adenocarcinoma, including a patient having colorectal cancer, containing allogeneic tumor cells and a physiologically acceptable carrier. The allogeneic tumor cells can be SW620, COLO 205, or SW403 cells. The invention composition can also contain an allogeneic cell expressing a cytokine. An allogeneic tumor cell can additionally express CD80. The invention additionally provides a method of stimulating an immune response in a patient having an adenocarcinoma, including a patient having colorectal cancer, by administering to the patient one or more allogeneic tumor cells, wherein the allogeneic cell stimulates an immune response to autologous tumor cells in the patient.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully